{"id":"W2778275419","doi":"10.1016/s2352-3026(17)30237-5","title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Anemia; Clinical trial; Phases of clinical research; Intention-to-treat analysis; Janus kinase inhibitor; Surgery; Gastroenterology; Janus kinase; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004308267,0.0004489796,0.002152471,0.00008905321,0.0004844923,0.0001917005,0.0006410302,0.0001562298,0.0003815118],"category_scores_gemma":[0.0002334816,0.000226096,0.00005911617,0.0001458877,0.0003902554,0.0002129374,0.0001356797,0.0003040422,0.0001648121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009810919,"about_ca_system_score_gemma":0.0002420877,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004118714,"about_ca_topic_score_gemma":0.000380101,"domain_scores_codex":[0.9975234,0.0002880126,0.0004987899,0.0006243167,0.0003133896,0.0007520874],"domain_scores_gemma":[0.9971254,0.0005358399,0.0005098055,0.001453618,0.0001955026,0.0001798082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7508371,0.004998944,0.2370608,0.00004990974,0.0005355105,0.0002515192,0.0002616813,7.783832e-7,0.00001206295,0.0004723069,0.002132732,0.003386629],"study_design_scores_gemma":[0.9516559,0.02521544,0.01771753,0.0003481806,0.0003646058,0.00006544631,0.00004172769,0.00001910498,0.001236718,0.00003084901,0.003007155,0.0002973058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816405,0.0002276766,0.00000309748,0.00277603,0.0001401348,0.007576644,0.00005878023,0.00005032037,0.007526887],"genre_scores_gemma":[0.9953083,0.000516605,0.0004586834,0.0004949636,0.0001731748,0.002224924,0.0001413871,0.00006411266,0.000617814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2193432,"threshold_uncertainty_score":0.9219929,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1158773631277653,"score_gpt":0.3732386234299219,"score_spread":0.2573612603021566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}